Longeveron Inc. (LGVN) stock
LGVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.92−0.19 (-9.00%)
Close on Nov 18, 2026Market cap $61.21MP/E –Yield –
Longeveron r&d expenses
Research and development expenses are spending on new products and technology.
Longeveron's R&D Expenses for the twelve months ending Jun 30, 2026 was $12.09M, up 25.1% year over year. For fiscal 2025 it was $12.04M, up 48.0% from the year before. The highest annual figure on record is $12.04M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.04M | +48.0% |
| FY2024 | Dec 31, 2024 | $8.14M | -10.2% |
| FY2023 | Dec 31, 2023 | $9.07M | -3.2% |
| FY2022 | Dec 31, 2022 | $9.37M | +32.1% |
| FY2021 | Dec 31, 2021 | $7.09M | +165.2% |
| FY2020 | Dec 31, 2020 | $2.67M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.19M | +8.1% |
| Q1 FY2026 | Mar 31, 2026 | $2.32M | -7.8% |
| Q4 FY2025 | Dec 31, 2025 | $2.72M | +36.8% |
| Q3 FY2025 | Sep 30, 2025 | $3.85M | +74.6% |
| Q2 FY2025 | Jun 30, 2025 | $2.95M | +71.5% |
| Q1 FY2025 | Mar 31, 2025 | $2.52M | +13.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.99M | -7.7% |
| Q3 FY2024 | Sep 30, 2024 | $2.21M | +19.7% |
| Q2 FY2024 | Jun 30, 2024 | $1.72M | -24.7% |
| Q1 FY2024 | Mar 31, 2024 | $2.22M | -20.2% |
| Q4 FY2023 | Dec 31, 2023 | $2.16M | +25.3% |
| Q3 FY2023 | Sep 30, 2023 | $1.84M | +42.6% |
| Q2 FY2023 | Jun 30, 2023 | $2.29M | +32.0% |
| Q1 FY2023 | Mar 31, 2023 | $2.78M | +35.7% |
| Q2 FY2022 | Jun 30, 2022 | $1.72M | -12.2% |
| Q1 FY2022 | Mar 31, 2022 | $1.29M | -4.3% |
| Q4 FY2021 | Dec 31, 2021 | $1.73M | +50.6% |
| Q3 FY2021 | Sep 30, 2021 | $2.05M | +250.1% |
| Q2 FY2021 | Jun 30, 2021 | $1.96M | +205.3% |
| Q1 FY2021 | Mar 31, 2021 | $1.35M | +367.1% |
| Q4 FY2020 | Dec 31, 2020 | $1.15M | – |
| Q3 FY2020 | Sep 30, 2020 | $585.00K | – |
| Q2 FY2020 | Jun 30, 2020 | $642.00K | – |
| Q1 FY2020 | Mar 31, 2020 | $289.00K | – |
See a number that looks wrong?